Gsk Share Discussion Threads

[jonjoneil] 25/3/2022 12:52

TM - you are guilty of missing my point. :-)

[tradermichael] 25/3/2022 12:34

jj - you are guilty of misinterpreting the CEO's remuneration.

GSK has previously moved to clarify the pay situation with its CEO, saying that some of the money gained was on a performance basis, and that her base pay increase is only two per cent.

[jonjoneil] 25/3/2022 12:03

TM - you will be pleased to see this 'good' publicity for GSK

More than 150 workers at pharmaceutical giant GSK begin voting on strike action today.

"The Industrial action ballot, involving staff at the company’s Barnard Castle site, in the North East, will end on 8 April.

Workers have already overwhelmingly turned down a below inflation pay offer of 4 per cent.

If they vote to strike the workers, who produce vaccines and medicines, could walk out at the end of April.

As workers struggle with the cost-of-living crisis, GSK CEO Emma Walmsley enjoyed a 17 per cent pay rise, to a whopping £8.2 million a year."



Although this is a biased union press release, that last point about EW's salary will make sure that all 150 workers will support the strike!
Although £8.2m is not excessive for a top 100 CEO, it's obscene for serial underperformance.

[tradermichael] 24/3/2022 14:56

London, 24 March 2022 - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved a label update for Cabenuva (cabotegravir, rilpivirine) making the oral lead-in with cabotegravir and rilpivirine tablets optional. Oral cabotegravir and rilpivirine can be taken for a month to assess tolerability to the medicines prior to initiating cabotegravir and rilpivirine injections, a regimen co-developed as part of a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, but this oral lead-in is now optional after clinical trial data demonstrated similar safety and efficacy profiles for both initiation methods (with or without the oral lead-in).

[porsche1945] 23/3/2022 10:03

Forget this crxp. Buy Tesla, it’s going to 1400, this IS financial advice haha.

[gateside] 21/3/2022 22:27

True!

Just glad I have shares in AZN as well :-)

[geckotheglorious] 21/3/2022 22:25

Who knows. Could be worse!
:)

[gateside] 21/3/2022 22:23

There's no hope for us then!

[geckotheglorious] 21/3/2022 22:13

GSK Pharmaceutical
Enjoy

[gateside] 21/3/2022 21:33

What will she be in charge of post split, GSK Pharmaceutical or Haelon the new Consumer arm?

[jonjoneil] 21/3/2022 20:43

TM
Nobody will accept that clarification. The most significant measure of CEO performance should be in shareholder value; so far she has failed on that criteria. She has had five full years to convince the Market of the direction she is taking the company! What's gone wrong?

[tradermichael] 21/3/2022 18:56

GSK has also moved to clarify the pay situation with its CEO, saying that some of the money gained was on a performance basis, and that her base pay increase is only two per cent.

[patientcapital] 18/3/2022 09:20

Looks like price is roughly where it was before the Unilever news. Unilever, on the other hand, has fallen.

[tradermichael] 17/3/2022 15:26

jj- LOL. There's no such thing as a bad review for GSK - all publicity is good publicity (but good point, anyway!)

[jonjoneil] 17/3/2022 15:14

TM - would you still thank me if it was a bad review? :-)

Nice to see price back over £16. (£16.40 including locked-in divi)

[tradermichael] 17/3/2022 13:11

jj- good review, thanks .....;0)

[jonjoneil] 17/3/2022 12:03

Moody's assigns rating to Haleon

[tradermichael] 15/3/2022 08:38

$1.30 = £1.00, good for GSK ..... ;o)

[jonjoneil] 14/3/2022 12:32

Net
I agree with your first statement. But not much sector circulation from AZN to GSK!

[netcurtains] 14/3/2022 12:08

jj: In my view, the "something wrong with the GSK valuation" is too simplistic.

The UK market is tiny and losing money to the USA all the time so we tend to get sector circulation where the UKs small amount of investment funds are swapped from one company to another.

Its all a bit ad hoc and random.

[jonjoneil] 14/3/2022 12:02

Trouble is TM, the market doesn't see it that way. They, like the Unilever shareholders, did not accept the £50bn valuation as realistic. Hence the current share price.

[tradermichael] 14/3/2022 11:32

GSK shareholders will receive stock in the new consumer health group amounting to at least 80% of the 68% stake that GSK currently owns in it. (Pfizer (PFE.N) owns the remaining 32%).
The £50bn Unilever offer for the CH group was rejected by GSK as fundamentally undervaluing the business.

On that basis, it underlines the massive undervaluation that the rump business of Pharma + vaccines holds, given that CH is currently only 28% of GSK's turnover and GSK's market capitalisation is only £77bn.

[panshanger1] 11/3/2022 17:31

Pierre Sounds like you need another cruise

[abdullla] 11/3/2022 17:08

Your last two lines explain it all.